相关实验视频

Updated: Jan 13, 2026

Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy

Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy

Published on: May 22, 2020

光热驱动的亚细胞离子转位和线粒体功能障碍用于增强瘤治疗

Jiayi Zhang¹, Wenfei Xu¹, Yuhui Xu²

¹Department of Translational Medicine Center, Beijing Chest Hospital/Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University, Beijing, China.

Advanced healthcare materials

|January 12, 2026

概括

这项研究介绍了一种新的纳米平台 (HCPH),通过调节离子和线粒体功能来增强光热疗法 (PTT). HCPH通过克服PTT的局限性和提高治疗效率来改善癌症治疗.

科学领域:

生物医学工程生物医学工程
纳米技术纳米技术
癌症治疗癌症治疗

背景情况:

光热疗法 (PTT) 提供精确的癌症治疗,但面临着诸如不均的加热和瘤耐热性等挑战,原因是热冲击蛋白90 (HSP90).
克服这些局限性需要创新的策略来提高PTT的有效性,并更有效地向癌细胞.

研究的目的:

通过调节亚细胞离子转位和诱导线粒体功能障碍,开发光热驱动纳米平台 (HCPH) 以加强癌症治疗.
为了研究黄素 (CUR) 和通过HCPH调解的PTT的协同效应,以改善治疗结果.

主要方法:

合成了HCPH,该HCPH由含有CUR和HA修饰的空洞中孔普鲁士蓝色纳米颗粒组成.
纳米平台的光热转换效率,通过CD44的向传递,以及在酸性条件下的CUR释放得到了评估.
这项研究检查了CUR诱导的内分泌网膜释放和PTT激活的TRPV1流对细胞稳定和线粒体功能的综合影响.

主要成果:

HCPH表现出卓越的光热转换效率和向瘤细胞.
CUR和PTT的协同作用导致细胞质和线粒体过载,诱导线粒体功能障碍并减少ATP合成.
这种调节障碍进一步抑制了HSP90的表达,创造了一个积极的反循环,增强了PTT的疗效.
在体外和体内研究证实了显著的瘤生长抑制和改善了HCPH治疗的治疗结果.

结论:

开发的HCPH纳米平台通过利用光热驱动的亚细胞转移并诱导线粒体损伤,有效地增强PTT.
这种新的方法提供了一个有前途的策略,以克服单模PTT的局限性,并提高癌症治疗效率.

关键词:

在Ca2+的超负荷下.增强光热效应的增强光热效应线粒体功能障碍线粒体功能障碍光热疗法是一种光热疗法.瘤特异性的协同疗法.

更多相关视频

Inducing Targeted Mild Hyperthermia in Murine Tumor Models through Photothermal Conversion of Near-infrared Light by Intratumoral Gold Nanorods

Inducing Targeted Mild Hyperthermia in Murine Tumor Models through Photothermal Conversion of Near-infrared Light by Intratumoral Gold Nanorods

Published on: October 10, 2025

Simultaneous Measurement of Mitochondrial Calcium and Mitochondrial Membrane Potential in Live Cells by Fluorescent Microscopy

Simultaneous Measurement of Mitochondrial Calcium and Mitochondrial Membrane Potential in Live Cells by Fluorescent Microscopy

Published on: January 24, 2017

相关概念视频

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.